Idera Pharma (NASDAQ:IDRA) reported positive preliminary data from its Phase 2 trial of tilsotolimod, in combination with Opdivo and Yervoy, in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC) patients.
To evaluate this triplet combination, patients received 8 mg of intratumoral tilsotolimod and 3 mg/kg of IV Opdivo every 2 weeks, along with 1 mg/kg of IV Yervoy every 8 weeks.
One patient experienced stable disease and nine patients progressed, as defined by RECIST v1.1. Six of the progressing patients had stability or reduction in size of injected lesions and six had stability or reduction in overall size of uninjected lesions.
Idera plans to enroll additional patients to further evaluate this triplet combination in MSS-CRC, with plans to increase the frequency of Yervoy dosing and limiting the number of allowed prior lines of treatment to two or fewer.
“We look forward to continuing to explore the potential clinical benefit of tilsotolimod in combination with ipilimumab and nivolumab in MSS-CRC, possibly yielding a treatment alternative for these patients with few current options,” Elizabeth Tarka, Idera’s CMO, said in a statement.
Enrollment of the next 10 patients is expected to begin in the fourth quarter of this year, with data anticipated in the second quarter of 2021.
